Combination therapy for lymphoma in patients 80 and older
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 80 years old
- You must have a type of lymphoma called DLBCL (diffuse large B-cell lymphoma) that tests positive for the CD20 protein
- You must not have had any previous treatment for this lymphoma
- You should have at least one tumor or lymph node that can be measured by scans
- Your general health should allow you to perform daily activities, and your blood counts and liver/kidney function should be within acceptable ranges
- You must be able to swallow the study medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.